Safety and Pharmacokinetics of IMT504, an Immunomodulator and Tissue Repair Inducer

Immune System Clinical Trial

— ECDA000/02  

Official title:

Phase 1 Open-label Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of IMT504 Phosphorothioate Oligonucleotide, an Immunomodulator and Tissue Repair Inducer, in Healthy Volunteers

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06312423
• Other study ID #: ECDA000/02
• Status: Recruiting
• Phase: Phase 1
• Start date: February 23, 2024
• Est. completion date: December 30, 2024

Study information

• Verified date: March 2024
• Source: Ministry of Public Health of the Province of La Rioja
• Contact: Ricardo A Lopez, Doctor
• Phone: 5491133016577
• Email: ralopez.new[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase 1 open-label dose-escalation study to evaluate the safety and pharmacokinetics of IMT504 Phosphorothioate Oligonucleotide, an immunomodulator and tissue repair inducer, in healthy volunteers.

Description:

This is a phase 1 open-label dose-escalation study to evaluate the safety and pharmacokinetics of IMT504 Phosphorothioate Oligonucleotide, an immunomodulator and tissue repair inducer, in healthy volunteers. A total of 12 adult volunteers of both sexes will be included, who will be progressively incorporated into 3 groups of 4 volunteers each. The first group will be administered subcutaneously with a single dose of 20 mg of IMT504. The second group will receive 3 doses (20 mg daily for 3 days) and then, if no toxicity is detected, the last group will be administered 5 daily doses of 20 mg/d.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: December 30, 2024
• Est. primary completion date: August 30, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female participants aged 18 years or older.

2. With the capacity and willingness to comply with the prohibitions and restrictions specified in the protocol.

3. In female volunteers of childbearing potential, negative pregnancy test at the beginning of the study and commitment to using a contraceptive method from the date of consent signing until 3 months after the study is completed.

4. Capable of reading and understanding all the features of the study.

5. Negative PCR (Polymerase Chain reaction) for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 ) virus;

6. Laboratory analysis without clinically significant variations within the 30 days prior to receiving the first dose of the investigational drug.

7. Negative serologies for hepatitis B virus (surface antigens [HBsAg] and antibodies against the core of hepatitis B virus [AntiHBc]), hepatitis C virus (AntiHCV), and human immunodeficiency virus (HIV).

8. Electrocardiogram (ECG) without evidence of acute or chronic significant pathologies.

9. Chest X-ray without significant pathological findings.

10. Capable of providing their signed and dated informed consent by the study volunteer and the authorized physician.

Exclusion Criteria:

1. Having participated in a research study within the 60 days prior to the start of the study.

2. Having a history of known allergies or a history of anaphylaxis or any other serious adverse reaction to any known drug or excipient.

3. History of alcoholism or substance abuse that would prevent compliance with the protocol characteristics.

4. Acute infectious disease at the time of enrollment or temperature =38.0°C in the 24 hours prior to the scheduled study vaccination.

5. Any laboratory abnormality with a severity grade >1 according to the Common Toxicity Criteria (CTC version 5 - November 2017).

6. Body Mass Index (BMI) greater than 35 kg/m2.

7. History of any active chronic disease.

8. Having received an investigational drug (including drugs related to COVID-19 prophylaxis or sepsis) or used an invasive investigational medical device in the 30 days prior to the start of the study.

9. Ongoing pregnancy or planned pregnancy within 3 months after administration of the investigational treatment, or lactation period.

10. Having undergone a surgical procedure requiring hospitalization in the 12 weeks prior to the start of the study, or not fully recovered from the surgery requiring hospitalization, or having a scheduled surgery requiring hospitalization during the expected study participation period or within 3 months after administration of the investigational treatment.

Related Conditions & MeSH terms

• Immune System

Intervention

Drug:
• Oligonucleotides, Phosphorothioate
Group 1: 20 mg/day single dose Group 2: 20 mg/day for 3 days Group 3: 20 mg/day for 5 days

Locations

Country	Name	City	State
Argentina	CENTRO DE INVESTIGACIÓN PARA ESTUDIOS DE FARMACOLOGÍA CLÍNICA DE FASE1 EN POBLACIÓN ADULTA y DE BIOEQUIVALENCIA. Sanatorio Nuestra Señora del Pilar	Buenos Aires

Sponsors (2)

Lead Sponsor	Collaborator
Ministry of Public Health of the Province of La Rioja	Immunalgia Therapeutics S.A.

Country where clinical trial is conducted

Argentina, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety: Local and systemic reaction after administration of each dose of the investigational drug	Number of volunteers overall and in each dose group with local or systemic reaction, based on evaluation of adverse event recorded during clinical assessments	Day 0, day 1 (group 1), days 1, 2, 3 (group 2) and days 1, 2, 3, 4, 5 (group 3), day 7 and day 28 after last administration of investigational drug
Primary	Safety: Serious adverse event	Number of volunteers overall and in each dose group with investigational drug - associated serious adverse events	Day 0 to day 28 after last administration of investigational drug
Primary	Safety: Variations in the Laboratory results	Number of volunteers overall and in each dose group with variations in laboratory results from baseline to different control	Day 0, day 1 (group 1), days 1, 2, 3 (group 2) and days 1, 2, 3, 4, 5 (group 3) and day 7 after last administration of investigational drug
Primary	Pharmacokinetics: IMT504 level in Serum	Blood samples taken at different times to evaluate: - Maximum concentration (Cmax) defined as the maximum plasma concentration of the drug during a dosing interval (peak)	0, 0.5, 1, 2, 4, 6, 8, 12, 24 hours after last administration of investigational drug
Primary	Pharmacokinetics: IMT504 level in Serum	Blood samples taken at different times to evaluate: - Maximum time (tmax): time necessary to reach Cmax (Tmax).	0, 0.5, 1, 2, 4, 6, 8, 12, 24 hours after last administration of investigational drug
Primary	Pharmacokinetics: IMT504 level in Serum	Blood samples taken at different times to evaluate: - Area under the curve (AUC): defined as "total exposure", it is the area under the concentration-time curve, and represents a function of the total amount of bioavailable drug.	0, 0.5, 1, 2, 4, 6, 8, 12, 24 hours after last administration of investigational drug
Primary	Pharmacokinetics: IMT504 level in Serum	Blood samples taken at different times to evaluate: - Half time (t1/2): defined as the time to reduce the drug concentration by half.	0, 0.5, 1, 2, 4, 6, 8, 12, 24 hours after last administration of investigational drug
Primary	Pharmacokinetics: IMT504 level in Serum	Blood samples taken at different times to evaluate: - Clearance (CL): Plasma volume of the product that is cleared per unit of time.	0, 0.5, 1, 2, 4, 6, 8, 12, 24 hours after last administration of investigational drug
Secondary	Pharmacodynamics: Interleukin - 35	Blood samples taken at different point of evaluation	0, 24 and 48 hours after last administration of investigational drug